179 related articles for article (PubMed ID: 16219481)
21. Cost-effectiveness of activated protein C in real-life clinical practice.
Dhainaut JF; Payet S; Vallet B; França LR; Annane D; Bollaert PE; Le Tulzo Y; Runge I; Malledant Y; Guidet B; Le Lay K; Launois R;
Crit Care; 2007; 11(5):R99. PubMed ID: 17822547
[TBL] [Abstract][Full Text] [Related]
22. Optimal approaches to the health economics of palliative care: report of an international think tank.
Gomes B; Harding R; Foley KM; Higginson IJ
J Pain Symptom Manage; 2009 Jul; 38(1):4-10. PubMed ID: 19615621
[TBL] [Abstract][Full Text] [Related]
23. Economic burden of epilepsy in a developing country: a retrospective cost analysis in China.
Hong Z; Qu B; Wu XT; Yang TH; Zhang Q; Zhou D
Epilepsia; 2009 Oct; 50(10):2192-8. PubMed ID: 19583782
[TBL] [Abstract][Full Text] [Related]
24. Health care cost associated with prostate cancer, androgen deprivation therapy and bone complications.
Krupski TL; Foley KA; Baser O; Long S; Macarios D; Litwin MS
J Urol; 2007 Oct; 178(4 Pt 1):1423-8. PubMed ID: 17706711
[TBL] [Abstract][Full Text] [Related]
25. Cumulative cost pattern comparison of prostate cancer treatments.
Wilson LS; Tesoro R; Elkin EP; Sadetsky N; Broering JM; Latini DM; DuChane J; Mody RR; Carroll PR
Cancer; 2007 Feb; 109(3):518-27. PubMed ID: 17186528
[TBL] [Abstract][Full Text] [Related]
26. The cost of radiation treatment at an Ontario regional cancer centre.
Wodinsky HB; Jenkin RD
CMAJ; 1987 Nov; 137(10):906-9. PubMed ID: 3676933
[TBL] [Abstract][Full Text] [Related]
27. Cost of depression in Europe.
Sobocki P; Jönsson B; Angst J; Rehnberg C
J Ment Health Policy Econ; 2006 Jun; 9(2):87-98. PubMed ID: 17007486
[TBL] [Abstract][Full Text] [Related]
28. Driving cost factors in adult outpatients with refractory epilepsy: a daily clinical practice in clinics of neurology in Spain.
Peña P; Sancho J; Rufo M; Martínez S; Rejas J;
Epilepsy Res; 2009 Feb; 83(2-3):133-43. PubMed ID: 19095410
[TBL] [Abstract][Full Text] [Related]
29. Breast cancer screening policies in developing countries: a cost-effectiveness analysis for India.
Okonkwo QL; Draisma G; der Kinderen A; Brown ML; de Koning HJ
J Natl Cancer Inst; 2008 Sep; 100(18):1290-300. PubMed ID: 18780864
[TBL] [Abstract][Full Text] [Related]
30. Cost effectiveness of paclitaxel-eluting stents for patients undergoing percutaneous coronary revascularization: results from the TAXUS-IV Trial.
Bakhai A; Stone GW; Mahoney E; Lavelle TA; Shi C; Berezin RH; Lahue BJ; Clark MA; Lacey MJ; Russell ME; Ellis SG; Hermiller JB; Cox DA; Cohen DJ;
J Am Coll Cardiol; 2006 Jul; 48(2):253-61. PubMed ID: 16843171
[TBL] [Abstract][Full Text] [Related]
31. Lifetime cost-effectiveness of prophylactic implantation of a cardioverter defibrillator in patients with reduced left ventricular systolic function: results of Markov modelling in a European population.
Cowie MR; Marshall D; Drummond M; Ferko N; Maschio M; Ekman M; de Roy L; Heidbuchel H; Verboven Y; Braunschweig F; Linde C; Boriani G
Europace; 2009 Jun; 11(6):716-26. PubMed ID: 19359333
[TBL] [Abstract][Full Text] [Related]
32. Cost-effectiveness of raising HDL cholesterol by adding prolonged-release nicotinic acid to statin therapy in the secondary prevention setting: a French perspective.
Roze S; Ferrières J; Bruckert E; Van Ganse E; Chapman MJ; Liens D; Renaudin C
Int J Clin Pract; 2007 Nov; 61(11):1805-11. PubMed ID: 17850322
[TBL] [Abstract][Full Text] [Related]
33. Retrospective study of the effect of skeletal complications on total medical care costs in patients with bone metastases of breast cancer seen in typical clinical practice.
Delea T; McKiernan J; Brandman J; Edelsberg J; Sung J; Raut M; Oster G
J Support Oncol; 2006; 4(7):341-7. PubMed ID: 16892696
[TBL] [Abstract][Full Text] [Related]
34. [Costs of radiotherapy and patient transportation].
Foulquier JN; Laugier A; Touboul E; Viardot JP; Schwartz LH
Bull Cancer Radiother; 1996; 83(3):170-1. PubMed ID: 8983263
[No Abstract] [Full Text] [Related]
35. Economic evaluation of single-fraction versus multiple-fraction palliative radiotherapy for painful bone metastases in breast, lung and prostate cancer.
Collinson L; Kvizhinadze G; Nair N; McLeod M; Blakely T
J Med Imaging Radiat Oncol; 2016 Oct; 60(5):650-660. PubMed ID: 27174870
[TBL] [Abstract][Full Text] [Related]
36. Cost of palliative radiation to the bone for patients with bone metastases secondary to breast or prostate cancer.
Hess G; Barlev A; Chung K; Hill JW; Fonseca E
Radiat Oncol; 2012 Oct; 7():168. PubMed ID: 23062178
[TBL] [Abstract][Full Text] [Related]
37. Advances in the treatment of lung cancer: economic and organizational aspects.
Mantini G; Trodella L; Balducci M; Turriziani A; Loffreda M; Manfrida S
Rays; 1999; 24(3):428-34. PubMed ID: 10605303
[TBL] [Abstract][Full Text] [Related]
38. Health economics in radiation oncology: introducing the ESTRO HERO project.
Lievens Y; Grau C
Radiother Oncol; 2012 Apr; 103(1):109-12. PubMed ID: 22325993
[TBL] [Abstract][Full Text] [Related]
39. [The cost of cancer in France: macroeconomic and microeconomic approaches, evolution towards a prospective payment system].
Perrier L; Borella L; Philip T
Bull Cancer; 2003 Nov; 90(11):1005-9. PubMed ID: 14706905
[TBL] [Abstract][Full Text] [Related]
40. Utility-adjusted analysis of the cost of palliative radiotherapy for bone metastases.
Barton MB; Jacob SA; Gebsky V
Australas Radiol; 2003 Sep; 47(3):274-8. PubMed ID: 12890248
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
